Drug maker names board members
A publicly traded drug maker has added two new directors to its board.
Perrigo (NYSE: PRGO), a Dublin-based company, which operates its North American base in Allegan, said today Geoffrey Parker and Theodore Samuels have been appointed to its board of directors.
The appointment of Parker, who will join the audit committee, was effective Monday. Samuels will join the board on Jan. 4, after his expected retirement from Capital Group.
Perrigo also said board members Mike Jandernoa and Gary Kunkle have elected not to stand for re-election in 2017.
Laurie Brlas, chairman of Perrigo’s board of directors, said Parker and Theodore align with the board’s strategy of bringing “a fresh perspective” to all aspects of the company.
“We look forward to benefiting from their relevant expertise and counsel as we continue to execute against our business objectives and take thoughtful and decisive action to create value for our shareholders,” she said.
She also thanked Jandernoa and Kunkle for their years of “dedication and service.”
Parker currently serves as a board member for Genomic Health, Sunesis Pharmaceuticals and ChemoCentryx.
He previously served as CFO of Anacor Pharmaceuticals from 2010 to 2015. From 1997 to 2009, he led the West Coast health care investment banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries.
He holds an A.B. degree in economics and engineering science from Dartmouth College and an M.B.A. from the Stanford Graduate School of Business.
Samuels has served as president of Capital Guardian Trust Company, a Capital Group company, since 2010 and an equity portfolio manager and investment analyst at Capital Group since 1981.
Samuels has evaluated numerous companies across all sectors and served on many management and investment committees, with an eye toward shareholder value creation.
He holds a B.A. from Harvard College and an M.B.A. from Harvard Business School.
Jandernoa and Kunkle
Jandernoa has been a director of Perrigo since January 1981. He served as Perrigo’s CEO from 1988 to 2000 and chairman of the board from 1991 to 2003. He also served in various other executive capacities with Perrigo since 1979.
Kunkle has been a director of Perrigo since 2002 and served as lead independent director from 2007 to 2008 and since 2009.